- 1 Prevalence of polymyxin resistant bacterial strains in India: a systematic
- 2 review and meta-analysis
- 5 Running title- Polymyxin-resistant bacterial strains in India
- 8 Sambit K. DWIBEDY<sup>1,2</sup>, Indira PADHY<sup>1</sup>, Aditya K. PANDA<sup>1,3</sup>, Saswat S.
- 9 **MOHAPATRA**<sup>1,3</sup>\*
- <sup>1</sup>Department of Biotechnology, Berhampur University, Bhanja Bihar, Berhampur- 760007,
- 12 Odisha, India

3

4

6

7

10

16

- <sup>2</sup>Department of Zoology, SBRG Women's College, Berhampur- 760001, Odisha, India
- <sup>3</sup>Centre of Excellence on Bioprospecting of Ethno-pharmaceuticals of Southern Odisha
- 15 (CoE-BESO), Berhampur University, Bhanja Bihar, Berhampur- 760007, India
- 18 For Correspondence-
- 19 Saswat S. Mohapatra, Ph.D.
- 20 Assistant Professor, Department of Biotechnology, Berhampur University, Bhanja Bihar,
- 21 Berhampur- 760007. Email: <a href="mailto:saswatsmohapatra@gmail.com">saswatsmohapatra@gmail.com</a>

Abstract

22

27

Introduction: Polymyxins, the cationic lipopeptide antibiotics, are the last line of therapeutics against the MDR Gram-negative bacterial (GNB) pathogens. Unfortunately, the

25 rising cases of polymyxin-resistant strains from across the globe have adversely impacted

26 their utility. While the molecular mechanisms responsible for developing polymyxin

resistance (Pol<sup>R</sup>) are largely understood, the prevalence of Pol<sup>R</sup> strains in India has not been

28 investigated systematically. The current study was undertaken to primarily determine the

29 prevalence of Pol<sup>R</sup> strains in India. Moreover, the extent of the spread of mobile colistin

resistance (*mcr*) genes among the GNB strains in India was also determined.

31 **Method:** A systematic search for articles using the relevant inclusion and exclusion criteria

was performed in the applicable databases for the period January 2015 to December 2023.

33 The included 41 studies were subjected to a meta-analysis using the Comprehensive Meta-

34 Analysis software (V.4). Publication biases were assessed using funnel plots and Egger's

35 regression analysis.

Result: Considering a total of 41 studies including 24,589 bacterial isolates the present meta-

analysis found the rate of Pol<sup>R</sup> bacteria in India to be at 15.0% (95% CI: 11.2 to 19.8).

Among the Indian States, Tamil Nadu topped with the highest prevalence of Pol<sup>R</sup> at 28.3%.

Investigating the contribution of the mcr genes, it was observed that among the Pol<sup>R</sup> strains,

40 8.4% (95% CI: 4.8 to 14.3) were *mcr* positive.

41 **Conclusion:** The study determined the prevalence of Pol<sup>R</sup> strains in India at 15.0% which is

higher than that of the global average at 10%. The study also determined that 8.4% of the

Pol<sup>R</sup> strains carried the *mcr* genes. The *mcr*-positive strains reported from India could be an

44 underestimation of the actual numbers due to the non-inclusion of mcr screening in many

45 previous studies. This study provides insight into the state of the Pol<sup>R</sup> situation in India,

which may be useful to develop a monitoring strategy to contain the spread of such strains

and preserve the efficacy of the polymyxins.

## INTRODUCTION

48

The significant use of antibiotics in healthcare, and agriculture, and their indiscriminate 49 50 prophylactic consumption has driven the rise of antibiotic-resistant bacterial pathogens. 51 Infections caused by antibiotic-resistant bacteria are increasingly becoming fatal due to the 52 non-availability of effective antibiotics against them. As per an estimate, drug-resistant pathogens caused 4.95 million deaths in 2019, which is predicted to rise to 10 million deaths 53 per annum by 2050.<sup>2</sup> Considering the significant economic consequences of rising drug-54 55 resistant infections, urgent mitigation measures are warranted. 56 Antibiotic-resistant bacteria belonging to the Gram-negative type pose a formidable challenge 57 to treatment as increasing reports of resistance to third and fourth generations of cephalosporins are reported globally.<sup>3</sup> In this unprecedented scenario, polymyxins, a group of 58 cationic lipopeptide antibiotics, remain the last option for treatment.<sup>4,5</sup> Polymyxin was 59 initially isolated in 1947 from a soil bacterium Paenibacillus polymyxa<sup>6</sup> and approved for 60 clinical use in 1959 against Gram-negative bacteria (GNB). Due to their nephrotoxic and 61 neurotoxic properties, polymyxins were prohibited for clinical use in the 1970 s<sup>7,8</sup> and were 62 consequently substituted by aminoglycosides, quinolones, and  $\beta$ -lactams. However, with the 63 64 rising infections caused by MDR GNB such as Klebsiella pneumoniae, Acinetobacter 65 baumannii, and Pseudomonas aeruginosa, and failure of the frontline antibiotics, polymyxins have re-emerged albeit with some modifications in the chemical structure as the last-resort 66 antibiotics against them. 4,9 67 Polymyxins are of five types (polymyxin A to polymyxin E), of which polymyxin B and 68 polymyxin E (colistin) are approved for clinical use. 10 Structurally, polymyxins are cationic 69 decapeptides consisting of a central cyclic heptapeptide with a tripeptide side-chain acylated 70 at the N-terminus by a fatty acid tail. 11,12 Polymyxins primarily target the negatively charged 71 72 outer membrane (OM) of GNB, where they disrupt the lipopolysaccharide (LPS) structure causing membrane damage and cell death. 5,13,14 73 The extensive use of polymyxins in the preceding decade in both healthcare and animal feeds 74 has triggered the emergence of polymyxin-resistant (Pol<sup>R</sup>) bacterial strains. Pol<sup>R</sup> bacterial 75 species such as K. pneumoniae, <sup>15-17</sup> P. aeruginosa, <sup>4,18</sup> A. baumannii, <sup>19</sup> E. coli, <sup>20</sup> Shigella 76 sonnei, 21 Salmonella enterica, 22 Enterobacter aerogenes and Enterobacter cloacae 23 have 77 78 been reported from across the globe adversely affecting the healthcare sector. Moreover, the

detection of Pol<sup>R</sup> GNB in both clinical and environmental samples has made the situation 79 80 concerning. The primary mechanism responsible for Pol<sup>R</sup> development is the OM remodelling or 81 modification in GNB making it increasingly positive [by the addition of 4-amino-4-deoxy L-82 arabinose (L-Ara4N) or phosphoethanolamine (pEtN)], leading to the repulsion of cationic 83 polymyxins. 4,13,24 The OM remodelling is generally carried out by bacterial two-component 84 signal transduction systems (TCS), of which PhoPQ and PmrAB are the prominent ones. 13,24 85 Moreover, bacterial species such as Serratia marcescens, Proteus mirabilis, Providencia 86 87 rettgeri, Vibrio cholerae, Campylobacter spp., Legionella spp., Morganella morganii, Burkholderia spp., Edwardsiella spp., Aeromonas hydrophila, Acinetobacter junii, Neisseria 88 89 spp. etc. are intrinsically resistant to polymyxins due to the permanent modification of their OM. 4,24,25 90 91 Chromosome-encoded polymyxin resistance though is the prevalent mechanism, bacteria can 92 acquire polymyxin resistance via the plasmid-borne mobile colistin resistance (mcr) gene. In this context, the first detection of mcr plasmids in 2015 from E. coli and K. pneumoniae 93 strains in China is significant.<sup>20</sup> The mcr gene encodes a pEtN transferase enzyme that 94 catalyses the addition of a pEtN residue to lipid-A moiety which alters the net charge of the 95 LPS. To date, ten different classes of mcr genes (mcr-1 to mcr-10) including several variants 96 have been discovered among many GNB pathogens. 26,27 Plasmids carrying mcr genes have 97 been reported from across the globe showing distinct geographical distribution. <sup>26,28</sup> As the 98 potential of rapid dissemination of plasmid-borne mcr genes is significantly high, it is 99 100 pertinent to conduct periodic surveillance to monitor their distribution in the environment and clinic. 101 In India, mcr genes have been reported in several studies conducted using clinical samples.<sup>29</sup> 102 hospital sewage,<sup>30</sup> urban sewage water,<sup>31</sup> and food samples.<sup>32</sup> However, a comprehensive 103 104 analysis of the distribution of mcr genes across India is lacking. It is important to highlight that the increasing number of carbapenem-resistant pathogenic bacteria has made India one of 105 106 the top users of polymyxins in the hospital setting. Furthermore, the use of colistin as a growth promoter in poultry farms has triggered the spread of Pol<sup>R</sup> GNB in the environment. 107 Though the Govt. of India has banned the use of colistin in farm animals since 2019, the 108 109 impact of their extensive use before 2019 is yet to be assessed.

- Studies reporting the prevalence of Pol<sup>R</sup> strains in India are very limited and the reports of mcr-positive bacterial strains are also rare. The current study employing a systematic review and meta-analysis was undertaken to gain an insight into the prevalence of Pol<sup>R</sup> bacterial strains across India from both clinical and environmental sources. Moreover, the study also attempted to estimate the mcr-positive bacterial strains in India with a particular emphasis on
- their geographical distribution in the Indian sub-continent.

## MATERIALS & METHODS

- Using published articles, the present systematic review and meta-analysis was conducted to
- determine the prevalence and spread of Pol<sup>R</sup> GNB from clinical and environmental sources in
- India and the contribution of mcr genes in gaining the Pol<sup>R</sup> phenotype. The study was
- undertaken as per the guidelines of Systematic Reviews and Meta-Analyses (PRISMA)<sup>33</sup>
- 121 (Fig. 1) (Supplementary Table 3).

## Data collection

116

122

130

- 123 The databases such as PubMed, Google Scholar, Science Direct, and Scopus were
- extensively searched using the keywords "polymyxin resistance", "colistin resistance",
- "mobile colistin resistance gene" and "India". Original studies reporting the presence of Pol<sup>R</sup>
- bacterial strains as well as mcr-positive strains in India, published between January 2015 to
- 127 December 2023 were included in this study. As the first report of mcr-positive bacterial
- strains came in 2015, <sup>20</sup> we selected the timeline from 2015 to 2023 for the meta-analysis to
- determine the prevalence of both Pol<sup>R</sup> and *mcr*-positive bacterial strains in India.

## **Inclusion criteria**

- 131 As the primary objective of the study was to determine the prevalence of Pol<sup>R</sup> bacterial
- strains in India, all studies reporting such strains irrespective of their origin were considered.
- Studies involving surveillance of hospital samples, sewage samples, food materials, etc. were
- analysed. A bacterial isolate was considered Pol<sup>R</sup> if the MIC to colistin was > 2 mg/L
- determined using the broth microdilution (BMD) method<sup>34,35</sup>, whereas a strain was
- considered *mcr*-positive if a particular *mcr* class or any of its variants was amplified by PCR.
- For the meta-analysis, the following inclusion criteria were followed: 1) the samples used in
- the studies must hail from India irrespective of their source of isolation, 2) data on resistance
- to polymyxin B and/or colistin must be available, 3) BMD method must have been used to
- determine Pol<sup>R</sup> of the bacterial isolates, 4) the article must mention the total sample size and
- the number of Pol<sup>R</sup> strains isolated or the prevalence frequency, 5) the sample size should not

be smaller than five for Pol<sup>R</sup> and one for *mcr* gene positive, and 6) the article must have been published in English.

Exclusion criteria

The following exclusion criteria were strictly followed during the analysis: 1) studies with no Pol<sup>R</sup> isolate were excluded; 2) studies conducted outside India were not considered; 3) studies

that employed resistance detection methods other than BMD were excluded; 4) studies that

were not published in English, were not peer-reviewed, and were published before 2015 were

149 excluded.

142143

144

145

146

147

148

150

157

159

161

163

164165

166

167

168

169

171

## **Data extraction**

Data were extracted from relevant articles that were qualified based on the study's inclusion and exclusion criteria (Fig. 1). Each report was individually screened and investigated for eligibility by two different authors (SKD and IP). Following a thorough review, the following information was extracted and summarised for each study: first author name, publication

year, State, or UT (Union Territories) of occurrence, total sample size, the total number of

Pol<sup>R</sup> isolates, reported Pol<sup>R</sup> bacteria, resistance detection method, genes involved in

resistance development, and mcr gene screening status. For further analysis, the data were

tabulated in a Microsoft Excel sheet.

## Subgrouping of data

160 The research articles with Pol<sup>R</sup> reports were classified into two groups based on criteria such

as sample size (more than five) and the involvement of *mcr* genes in the development of Pol<sup>R</sup>.

Studies reporting a specific number of samples containing both Pol<sup>R</sup> and susceptible isolates

and a particular number of Pol<sup>R</sup> bacteria as events were placed in the first group. This group

was further subdivided based on two criteria: geographical location (the States or UTs from

where they were reported) and the source of their isolation (clinical or environmental). In this

classification system, those States were included that have at least four different reports on

Pol<sup>R</sup> isolates. In the second group, those reports were included where mcr gene screening

status was mentioned clearly in the study.

#### **Quality assessment**

170 The quality of all eligible reports was determined by the Newcastle–Ottawa Scale (NOS) and

only the high-quality reports were considered for the present meta-analysis. According to the

- NOS guidelines, qualitative scores are given as stars, and a total score of five stars or more
- for a study is considered a high-quality report.

## Meta-analysis

174

- 175 The meta-analysis was performed using the relevant studies and reports to determine the
- prevalence of Pol<sup>R</sup> bacteria in India, and the contribution of *mcr* genes in Pol<sup>R</sup> phenotype. All
- statistical analyses were performed using the Comprehensive Meta-Analysis (CMA) software
- 178 (version 4.0; Biostat Inc. USA). The generated data were visualized using forest plots.
- Publication bias in the included studies was assessed using funnel plots with visual analysis<sup>36</sup>
- and Egger regression analysis.<sup>37</sup> The heterogeneity of the studies was examined using the
- 181 Cochrane Q statistics<sup>38</sup> and I<sup>2</sup> statistics.<sup>39</sup> Based on the outcome of the heterogeneity analysis,
- a fixed-effect model (homogenous) or random-effect model (heterogeneous) was used for the
- meta-analysis.
- The combined event rate and 95% confidence interval were calculated to determine the
- frequency of Pol<sup>R</sup> isolates in India and the contribution of *mcr* to polymyxin resistance. In
- addition, sensitivity analysis was performed to explore the robustness of the meta-analysis by
- excluding one study at a time, performing the meta-analysis, and comparing it with the results
- of the parent analysis.

## RESULTS

189

190

198

#### Literature review and screened results

- Overall, 1408 articles were obtained by searching different databases with suitable keywords
- 192 (PubMed = 802, Google Scholar = 431, Science Direct = 109, Scopus = 66). The article
- selection approach is presented in the PRISMA flow chart (Fig. 1). A total of 41 eligible
- articles reporting Pol<sup>R</sup> (Supplementary Table 1) were included in the meta-analysis. For
- determining the contribution of *mcr* genes in Pol<sup>R</sup>, 58 studies were considered of which 40
- studies were found to be eligible for the meta-analysis (Supplementary Table 2) based on the
- 197 stipulated inclusion and exclusion criteria.

#### **Publication bias**

- 199 Visual analysis of the funnel plot and Egger's regression analysis showed the absence of
- publication bias in the analysis of the incidence of Pol<sup>R</sup> bacteria in India (intercept: 0.37, 95%)
- 201 CI: -2.73 to 3.46, p = 0.81), as well as in the analysis of the role of the mcr gene in Pol<sup>R</sup>
- 202 (intercept: -1.3, 95% CI: -2.69 to 0.08, p = 0.065) (Table 1) (Supplementary Fig. 1).

- 203 Furthermore, after the categorization of all studies according to the geographical locations
- 204 (States) from which they were reported, the funnel plot and Egger's regression analysis
- revealed no significant biases while analysing the incidence of Pol<sup>R</sup> bacteria in states such as
- Delhi, Odisha, Tamil Nadu, and Uttar Pradesh (Table 1) (Supplementary Fig. 2).

#### Heterogeneity analysis

207

210

231

- 208 Cochrane Q and I<sup>2</sup> measurements demonstrated significant heterogeneity among the included
- studies. Hence, a random-effects model was used for all meta-analyses (Table 1).

# Prevalence of Pol<sup>R</sup> bacteria in India

- 211 After analysing 41 reports, accounting for 24,589 bacterial isolates tested, the present meta-
- analysis found that the rate of Pol<sup>R</sup> bacteria in India was 15.0% (95% CI: 11.2 to 19.8) (Fig.
- 213 2A). Out of the 28 states and eight UTs in India, 12 states and 3 UTs have reported the
- presence of Pol<sup>R</sup> bacterial strains. Interestingly, 16 states and 5 UTs in India have not
- reported the presence of Pol<sup>R</sup> strains. The overall spread of the Pol<sup>R</sup> GNB strains in the Indian
- subcontinent is shown in Fig. 2B. Among all the states that have reported Pol<sup>R</sup>, Tamil Nadu,
- Uttar Pradesh, and Odisha are the top three with the rate of Pol<sup>R</sup> at 28.3%, 16.3%, and 15.9%,
- respectively, which is higher than the overall prevalence of Pol<sup>R</sup> in the Indian subcontinent
- 219 (Fig. 3). Moreover, among the other states in India Pol<sup>R</sup> prevalence in Delhi was found to be
- 220 quite high at 13.7%, though less than the national average (Fig. 3).
- A breakdown of the Pol<sup>R</sup> GNB strains by the source of their isolation revealed that 89%
- 222 (1875 isolates) of them were from clinical sources, whereas the remaining 11% (227 isolates)
- were from the environmental samples (Fig. 4A). Bacterial strains isolated in hospitals from
- various samples such as stool, pus, urine, wound etc. were considered as clinical isolates
- 225 though further sub-categorization was not performed in the current study. However, among
- the environmental sources, water (46%), vegetables (45%), poultry products (8%), and dairy
- farms (1%) were the major contributors for Pol<sup>R</sup> strains (Fig. 4A). Employing meta-analysis
- on 36 eligible clinical reports, the rate of Pol<sup>R</sup> was found to be 13.5% (95% CI: 10.0 to 17.9)
- 229 (Fig. 4B), whereas a similar analysis using 5 environmental reports the Pol<sup>R</sup> rate was found to
- 230 be 27.6% (95% CI: 11.0 to 54.2) (Fig. 4C).

## Role of *mcr* gene in the development of Pol<sup>R</sup>

- To understand the prevalence of *mcr* genes in Pol<sup>R</sup> bacterial isolates in India in comparison
- with other possible mechanisms, 40 eligible reports with positive mcr gene screening status

- and a sample size of more than one (Pol<sup>R</sup> isolate) criterion were considered for the analysis
- 235 (Supplementary Table 2). Out of the 1606 bacterial isolates tested for the presence of mcr
- genes by PCR, 76 strains were found to be positive. The meta-analysis result showed that the
- contribution of the *mcr* gene to the rise in polymyxin resistance was 8.4% (95% CI: 4.8-14.3)
- in India (Fig. 5A).
- 239 Analysing the State wise detection of the mcr genes, nine states were found to have reported
- 240 the presence of mcr genes (Fig. 5B), among which Uttar Pradesh has the highest number of
- reports at 48 followed by Tamil Nadu and Assam with 31 and 15 reports respectively.
- Analysing the prevalence of particular classes of *mcr* genes, it was revealed that in India, so
- far six classes of mcr genes namely mcr-1, mcr-2, mcr-3, mcr-4, mcr-5, and mcr-9 have been
- 244 detected (Table 2). Among the *mcr* classes, the present analysis identified the *mcr-1* to be the
- predominant one and found in 72% of the isolates, whereas the frequencies of mcr-2, mcr-3,
- 246 *mcr-4*, *mcr-5*, and *mcr-9* were 3%, 19%, 3%, 1%, and 2%, respectively (Fig. 5C).

## Sensitivity analysis

247

254

- 248 Sensitivity analysis was performed to measure the robustness of the meta-analysis by
- excluding a single study each time and relating the results to the parental meta-analysis. As
- 250 illustrated in Supplementary Fig. 3, no significant deviation was observed in the sensitivity
- analysis compared with the original meta-analysis results for studying the incidence of Pol<sup>R</sup>
- bacteria in India. Furthermore, the meta-analysis on the contribution of the *mcr* genes to Pol<sup>R</sup>
- also revealed a robust observation, as shown in Supplementary Fig. 4.

## DISCUSSION

- 255 The current meta-analysis systematically evaluated the prevalence of Pol<sup>R</sup> bacteria in India,
- which was higher than the global average. In this study, we found that 15.0% of GNB were
- Pol<sup>R</sup> (Fig. 2), whereas the global average remained at 10%. 40 A previous study has put the
- 258 rate of Pol<sup>R</sup> among clinical Enterobacteriaceae isolates in India at 13.8%.<sup>41</sup>
- 259 The present study revealed that GNB resistant to polymyxins is spread all over India, and
- 260 States like Tamil Nadu, Uttar Pradesh, and Odisha have a higher prevalence of Pol<sup>R</sup> strains
- 261 than the national average (Fig. 2B, Fig. 3). The rising incidence of Pol<sup>R</sup> in India could be
- 262 attributed to their indiscriminate use in the healthcare sector, in poultry farms as growth
- promoters, and the rapid dissemination of mcr genes via horizontal gene transfer. Even
- 264 though India has banned the use of colistin in animal feeds since 2019, its implications on the
- spread of Pol<sup>R</sup> may be revealed a few years down the line. Interestingly, there are no reports

of Pol<sup>R</sup> in 16 states and 5 UTs in India, which may be due to the lack of surveillance in those 266 267 States and UTs (Fig. 2B). Although most of the reports used in this study indicated Pol<sup>R</sup> rates under 20%, there are a 268 few that have reported significantly higher Pol<sup>R</sup> rates. 42-47 These high numbers are possibly 269 due to the different methodologies adopted for determining polymyxin resistance. In India, 270 271 various methods such as the Kirby-Bauer disk diffusion test, BMD, agar dilution, Etest, 272 VITEK-2, gradient diffusion, colistin broth disc elution, rapid polymyxin Nordmann Poirel 273 Test, Mikrolatest kit, BD Phoenix M50, MicroScan WalkAway 96 Plus, Micronaut-S and 274 Modified Stokes DDT, have been used. However, as per the recommendation of the CLSI 275 and EUCAST, BMD is the only approved method for determining polymyxin 276 susceptibility, <sup>34,35</sup> and therefore in this study, the polymyxin resistance reports determined using the BMD method have only been included. 277 278 Though the primary goal of this meta-analysis was to find the overall prevalence of Pol<sup>R</sup> 279 bacterial strains in India, our study revealed that 13.5% of the clinical isolates and 27.6% of 280 the environmental isolates from India are resistant to polymyxins (Fig. 4). However, there 281 were only five eligible studies that were used to analyse the environmental samples (Fig. 4C). 282 Therefore, a larger study might be needed to confirm the observed high rate of resistance 283 among the environmental isolates. This study revealed that in 8.4% of cases, the mcr gene was responsible for the Pol<sup>R</sup> 284 phenotype (Fig. 5A). In India, after the first detection of the mcr gene in a clinical E. coli 285 isolate, <sup>48</sup> several reports of *mcr* occurrence have been published. <sup>30,32,49–51</sup> To date, six classes 286 287 of mcr genes have been reported in India: mcr-1, mcr-2, mcr-3, mcr-4, mcr-5, and mcr-9 288 (Table 2). Of the ten different mcr classes described till date, mcr-1 was the predominant variant responsible for driving polymyxin resistance in India. In the current study, the 289 290 frequency of mcr-1 was 72% (Fig. 5C). Our analysis corroborates the recent studies that have determined the predominance of mcr-1 gene in comparison to other mcr classes in the spread 291 of colistin resistance. 52-54 Considering that mcr-1 was the first plasmid-borne colistin 292 resistance gene to be detected<sup>20</sup> it has spread across the globe in the preceding decade or so. 293 Moreover, various retrospective surveillance for mcr genes have revealed their presence in 294 295 samples dating back to 1980s highlighting their presence before the widespread use of colistin in the animal feeds, which has only supplemented its global spread. 26,55 296

Unlike the distribution of Pol<sup>R</sup> GNB, the spread of mcr has been limited to nine states and two UTs in India (Fig. 5B). Among these states, Uttar Pradesh was found to be the hotspot for the spread of mcr variants, with 48 reports, followed by Tamil Nadu and Assam with 31 and 15 mcr positive reports, respectively (Supplementary Table 2). However, several reports on Pol<sup>R</sup> have not provided sufficient information on mcr gene screening status. The limited screening for mcr genes among these studies may be responsible for the low rate of detection and reporting of mcr genes in India. As mentioned previously, mcr genes are largely plasmid-borne, and various types of plasmids are involved in carrying mcr genes in GNB. 26,56 In India, different mcr variants were found to be linked with plasmids including IncHI2, InCHI2A, IncX1, IncX4, and FIA Inc. 32,43,57 The role of these plasmids conferring resistance to carbapenems, cephalosporins, and fosfomycin has also been established previously. 58,59 Although plasmids are the primary mobile genetic elements through which mcr genes disseminate among bacterial species, their chromosomal integration has also been reported in different bacterial species in India. 60-63 The major advantage of chromosomal integration of mcr genes could be their efficient vertical transmission in the absence of polymyxin selection. Some intrinsically resistant bacteria also harbour the mcr genes and can potentially spread them to the polymyxin-susceptible species in the environment.<sup>64</sup> Moreover, few studies have reported the presence of the mcr-1, mcr-3, and mcr-9 genes in bacterial species that are susceptible to polymyxin. 51,65 This is primarily due to the insertional inactivation of mcr-1 and mcr-3 genes. 51,65 However, in the case of mcr-9 positive Enterobacter hormaechei strain, qseBC TCS genes were absent downstream<sup>66</sup> which has been previously described to induce the colistin resistance phenotype by upregulating the mcr-9 gene expression in response to the subinhibitory concentration of colistin.<sup>67</sup> This meta-analysis has certain limitations. First, the current study included articles available in the English language only, as a result, publications in other languages have been excluded. Second, we searched reports from databases including PubMed, Google Scholar, Scopus, and Science Direct, so may have missed publications indexed in other databases. Third, as certain GNB species are intrinsically resistant to polymyxins, reports on polymyxin resistance from the environmental strains may have been biased toward such species.

## **CONCLUSION**

297 298

299

300

301 302

303

304

305

306

307

308

309

310311

312

313

314

315

316317

318

319

320

321

322

323

324

325

326

The present study found that the rate of Pol<sup>R</sup> bacterial strains in India was 15.0%, which is higher than the global average. Pol<sup>R</sup> was determined among 13.5% and 27.6% of the bacterial isolates from the clinical and environmental sources respectively. While Pol<sup>R</sup> strains have 330 been reported from most of the Indian States and UTs, there are still regions where adequate 331 332 data are not available, warranting monitoring and surveillance. This study further found that in 8.4% of Pol<sup>R</sup> strains, the phenotype was determined by mcr genes carried on plasmids. 333 This may be grossly underestimated due to the lack of mcr surveillance data in many published articles. As polymyxins are one of the last option antibiotics available against GNB pathogens, efforts to increase their clinical longevity is paramount. However, the increasing incidence of polymyxin resistance in clinics and the environment has the potential to limit 338 antibiotic treatment options. Therefore, along with developing better versions of polymyxins and/or their derivatives, it is also important to devise strategies for monitoring the frequency of Pol<sup>R</sup> bacterial species and, the prevalence of mcr genes in them. Sustained measures need 340 341 to be in place to contain further spread of the polymyxin resistance phenotype in the near 342 future.

#### 343 **Author Contributions**

- 344 Conceptualization: SKD, AKP, and SSM; Data extraction and analysis: SKD, IP, AKP, and
- 345 SSM; Data validation: SKD and IP; Manuscript writing and reviewing: SKD, AKP, and
- 346 SSM. All authors agreed to the submitted version.

#### 347 Funding

328

329

334

335

336

337

339

- 348 This work is supported by the funds received from the Science and Technology Department,
- 349 Govt. of Odisha (Grant no. ST-BT-MISC-0005-2023-2463/ST, dt. 23-05-2023).
- 350 Infrastructure support from the "Centre of Excellence on Bioprospecting of Ethno-
- pharmaceuticals of Southern Odisha (CoE-BESO)" to the Dept. of Biotechnology, 351
- 352 Berhampur University is gratefully acknowledged. Indira Padhy is a recipient of the "Biju
- 353 Patnaik Research Fellowship (BPRF)" from the Science and Technology Department, Govt.
- 354 of Odisha.

#### 355 **Transparency Declarations**

- 356 The authors declare that the research was conducted in the absence of any commercial or
- 357 financial relationships that could be construed as a potential conflict of interest.

#### 358 **Legends to Figures**

359 **Figure. 1.** The PRISMA flow diagram for the selection, inclusion, and exclusion of studies.

- 360 Figure. 2. (A) Forest plots demonstrating the event rate of Pol<sup>R</sup> bacteria in India. The
- 361 Comprehensive Meta-Analysis software V4 (Biostat Inc. USA) was used for the calculation
- of the event rate and 95% confidence interval. (B) Distribution of Pol<sup>R</sup> bacteria across
- different States and Union Territories (UTs) of India from 41 studies. States and UTs in India
- that have reported Pol<sup>R</sup> strains are shaded in green.
- Figure. 3. Forest plots representing the event rate of Pol<sup>R</sup> bacteria in different states of India
- 366 (A) Delhi, (B) Odisha, (C) Tamil Nadu, and (D) Uttar Pradesh.
- Figure. 4. (A) Pie chart showing the prevalence of Pol<sup>R</sup> bacteria in India based on the source
- of their isolation. (B) Forest plots revealing the event rate of Pol<sup>R</sup> bacteria in clinical isolates
- in India. (C) Forest plots demonstrating the event rate of Pol<sup>R</sup> bacteria in environmental
- 370 isolates in India.
- Figure. 5. (A) Forest plots demonstrating the contribution of the mcr genes in the
- development of polymyxin resistance in India. (B) Spread of mcr genes across different
- 373 States and UTs of India. States and UTs that have reported *mcr*-positive strains are shaded in
- orange. (C) Pie chart showing the prevalence of reported classes of *mcr* genes in India.

#### REFERENCES

- 1. Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019:
- 377 a systematic analysis. *The Lancet* 2022: S0140673621027240.
- 2. O'Neill J. An audience with Jim O'Neill. Nat Rev Drug Discov 2016; 15: 526–526.
- 3. Darby EM, Trampari E, Siasat P, et al. Molecular mechanisms of antibiotic resistance revisited. Nat
- 380 *Rev Microbiol* 2023; **21**: 280–95.
- 4. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and
- 382 Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev 2017; 30: 557–
- 383 96.

- 5. Mohapatra SS, Dwibedy SK, Padhy I. Polymyxins, the last-resort antibiotics: Mode of action,
- resistance emergence, and potential solutions. *J Biosci* 2021; **46**: 85.
- 6. Benedict RG, Langlykke AF. Antibiotic activity of Bacillus polymyxa. *J Bacteriol* 1947; **54**: 24.
- 7. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate.
- 388 Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72:
- 389 857–68.
- 8. Nation RL, Li J. Colistin in the 21st century: *Curr Opin Infect Dis* 2009; **22**: 535–43.
- 391 9. Vaara M. Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics. Front
- 392 *Microbiol* 2019; **10**: 1689.
- 393 10. Hamel M, Rolain J-M, Baron SA. The History of Colistin Resistance Mechanisms in Bacteria:
- Progress and Challenges. *Microorganisms* 2021; **9**: 442.
- 395 11. Kwa A, Kasiakou SK, Tam VH, et al. Polymyxin B: similarities to and differences from colistin
- 396 (polymyxin E). Expert Rev Anti Infect Ther 2007; 5: 811–21.
- 397 12. Nang SC, Azad MAK, Velkov T, et al. Rescuing the Last-Line Polymyxins: Achievements and
- 398 Challenges Barker E, ed. *Pharmacol Rev* 2021; **73**: 679–728.
- 399 13. Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and intrinsic
- resistance in bacteria. Front Microbiol 2014; 5: 643.
- 401 14. Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial Mechanisms of Polymyxin and Bacterial
- 402 Resistance. *BioMed Res Int* 2015; **2015**: 1–11.
- 403 15. Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella
- 404 pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob
- 405 *Chemother* 2007; **59**: 786–90.
- 406 16. Lim LM, Ly N, Anderson D, et al. Resurgence of Colistin: A Review of Resistance, Toxicity,
- 407 Pharmacodynamics, and Dosing. *Pharmacotherapy* 2010; **30**: 1279–91.
- 408 17. Elemam A, Rahimian J, Doymaz M. In Vitro Evaluation of Antibiotic Synergy for Polymyxin B-
- 409 Resistant Carbapenemase-Producing Klebsiella pneumoniae. J Clin Microbiol 2010; 48: 3558–62.

- 410 18. El-Baky RMA, Masoud SM, Mohamed DS, et al. Prevalence and Some Possible Mechanisms of
- 411 Colistin Resistance Among Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas
- aeruginosa. Infect Drug Resist 2020; 13: 323.
- 413 19. Hejnar P, Kolář M, Hájek V. Characteristics of Acinetobacter strains (phenotypic classification,
- antibiotic susceptibility and production of \( \beta \)-lactamases) isolated from Haemocultures from patients at
- the teaching hospital in Olomouc. *Acta Univ Palacki Olomuc Fac Med* 1999; **142**:73-71999.
- 416 20. Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance
- 417 mechanism MCR-1 in animals and human beings in China: a microbiological and molecular
- 418 biological study. *Lancet Infect Dis* 2016; **16**: 161–8.
- 419 21. Ma Q, Huang Y, Wang J, et al. Multidrug-resistant Shigella sonnei carrying the plasmid-mediated
- 420 mcr -1 gene in China. *Int J Antimicrob Agents* 2018; **52**: 14–21.
- 421 22. Borowiak M, Fischer J, Hammerl JA, et al. Identification of a novel transposon-associated
- 422 phosphoethanolamine transferase gene, mcr-5, conferring colistin resistance in d-tartrate fermenting
- 423 Salmonella enterica subsp. enterica serovar Paratyphi B. *J Antimicrob Chemother* 2017; **72**: 3317–24.
- 424 23. Zeng K, Doi Y, Patil S, et al. Emergence of the Plasmid-Mediated mcr-1 Gene in Colistin-
- Resistant Enterobacter aerogenes and Enterobacter cloacae. Antimicrob Agents Chemother 2016; 60:
- 426 3862-3.
- 427 24. Padhy I, Dwibedy SK, Mohapatra SS. A molecular overview of the polymyxin-LPS interaction in
- 428 the context of its mode of action and resistance development. *Microbiol Res* 2024; **283**: 127679.
- 429 25. Yin W, Li H, Shen Y, et al. Novel Plasmid-Mediated Colistin Resistance Gene mcr-3 in
- 430 *Escherichia coli* Bush K, ed. *mBio* 2017; **8**: e00543-17.
- 431 26. Nang SC, Li J, Velkov T. The rise and spread of mcr plasmid-mediated polymyxin resistance. Crit
- 432 Rev Microbiol 2019; **45**: 131–61.
- 433 27. Gaballa A, Wiedmann M, Carroll LM. More than mcr: canonical plasmid- and transposon-
- 434 encoded mobilized colistin resistance genes represent a subset of phosphoethanolamine transferases.
- 435 Front Cell Infect Microbiol 2023; **13**: 1060519.
- 436 28. Gogry FA, Siddiqui MT, Sultan I, et al. Current Update on Intrinsic and Acquired Colistin
- 437 Resistance Mechanisms in Bacteria. *Front Med* 2021; **8**: 677720.
- 438 29. Singh S, Pathak A, Rahman M, et al. Genetic Characterisation of Colistin Resistant Klebsiella
- 439 pneumoniae Clinical Isolates From North India. Front Cell Infect Microbiol 2021; 11: 666030.
- 440 30. Talat A, Usmani A, Khan AU. Detection of E. coli IncX1 Plasmid-Mediated mcr-5.1 Gene in an
- 441 Indian Hospital Sewage Water Using Shotgun Metagenomic Sequencing: A First Report. Microb
- 442 Drug Resist 2022; 28: 759–64.
- 443 31. Gogry FA, Siddiqui MT, Haq. QMohdR. Emergence of mcr-1 conferred colistin resistance among
- bacterial isolates from urban sewage water in India. *Environ Sci Pollut Res* 2019; **26**: 33715–7.
- 32. Ghafur A, Shankar C, GnanaSoundari P, et al. Detection of chromosomal and plasmid-mediated
- 446 mechanisms of colistin resistance in Escherichia coli and Klebsiella pneumoniae from Indian food
- 447 samples. *J Glob Antimicrob Resist* 2019; **16**: 48–52.

- 448 33. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for Reporting of
- 449 Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist
- 450 and Explanations. *Ann Intern Med* 2015; **162**: 777–84.
- 451 34. Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and Laboratory Standards Institute and
- 452 European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B
- and Colistin Clinical Breakpoints. Clin Infect Dis 2020: ciaa121.
- 454 35. CLSI. Colistin Breakpoints for Pseudomonas aeruginosa and Acinetobacter spp. In: Wayne PA,
- 455 ed. CLSI Rationale Document MR01. 1st ed. Clinical and Laboratory Standards Institute, 2018.
- 456 36. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.
- 457 *J Clin Epidemiol* 2001; **54**: 1046–55.
- 458 37. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical
- 459 test. BMJ 1997; **315**: 629–34.
- 460 38. Higgins JPT, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions. The
- 461 Cochrane Collaboration; 2011. Available at: www.handbook.cochrane.org.
- 462 39. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ
- 463 2003; **327**: 557.
- 464 40. Silva KED, Rossato L, Leite AF, et al. Overview of polymyxin resistance in Enterobacteriaceae.
- 465 Rev Soc Bras Med Trop 2022; **55**: e0349-2021.
- 466 41. Turnidge JD, Bell JM, Jones RN. Emergence of Colistin-Resistant Klebsiella spp., and
- 467 Enterobacter spp. in the Asia-Pacific (APAC) Region: A SENTRY Antimicrobial Surveillance
- 468 Program Report (2006). In: Washington DC: American Society for Microbiology, 2007.
- 469 42. Bardhan T, Chakraborty M, Bhattacharjee B. Prevalence of Colistin-Resistant, Carbapenem-
- 470 Hydrolyzing Proteobacteria in Hospital Water Bodies and Out-Falls of West Bengal, India. Int J
- 471 Environ Res Public Health 2020; **17**: 1007.
- 472 43. Palani GS, Ghafur A, Krishnan P, et al. Intestinal carriage of colistin resistant Enterobacteriaceae
- in hospitalized patients from an Indian center. *Diagn Microbiol Infect Dis* 2020; **97**: 114998.
- 474 44. Priyanka, Meena PR, Meghwanshi KK, et al. Leafy greens as a potential source of multidrug-
- 475 resistant diarrhoeagenic Escherichia coli and Salmonella. Microbiol Read Engl 2021; 167.
- 476 45. Rohilla R, Raina D, Singh M, et al. Evaluation of Sphingomonas paucimobilis as an emerging
- 477 nosocomial pathogen in a teaching hospital in Uttarakhand. *Iran J Microbiol* 2021; **13**: 617–23.
- 478 46. Shanthini T, Manohar P, Hua X, et al. Detection of Hypervirulent Klebsiella pneumoniae from
- 479 Clinical Samples in Tamil Nadu. 2023: 2023.02.19.23286158.
- 480 47. Shekhar C, Joshi N, Singh A. Prevalence of Multidrug-Resistant Escherichia coli in Drinking-
- Water in and around Ayodhya (U.P.), India. Indian J Vet Sci Biotechnol 2023; 19: 112–5.
- 48. Kumar M, Saha S, Subudhi E. More Furious Than Ever: Escherichia coli -Acquired Co-resistance
- Toward Colistin and Carbapenems. Clin Infect Dis 2016: ciw508.
- 49. Marathe NP, Pal C, Gaikwad SS, et al. Untreated urban waste contaminates Indian river sediments
- with resistance genes to last resort antibiotics. *Water Res* 2017; **124**: 388–97.

- 486 50. Mitra S, Basu S, Rath S, et al. Colistin resistance in Gram-negative ocular infections: prevalence,
- 487 clinical outcome and antibiotic susceptibility patterns. *Int Ophthalmol* 2020; **40**: 1307–17.
- 488 51. Ragupathi NKD, Sethuvel DPM, Anandan S, et al. First hybrid complete genome of Aeromonas
- 489 veronii reveals chromosome-mediated novel structural variant mcr-3.30 from a human clinical
- 490 sample. Access Microbiol 2020; 2.
- 491 52. Dadashi M, Sameni F, Bostanshirin N, et al. Global prevalence and molecular epidemiology of
- 492 mcr-mediated colistin resistance in Escherichia coli clinical isolates: a systematic review. J Glob
- 493 *Antimicrob Resist* 2022; **29**: 444–61.
- 494 53. Portes AB, Rodrigues G, Leitão MP, et al. Global distribution of plasmid □ mediated colistin
- 495 resistance mcr gene in Salmonella: A systematic review. J Appl Microbiol 2021: jam.15282.
- 496 54. Bastidas-Caldes C, De Waard JH, Salgado MS, et al. Worldwide Prevalence of mcr-mediated
- 497 Colistin-Resistance Escherichia coli in Isolates of Clinical Samples, Healthy Humans, and
- 498 Livestock—A Systematic Review and Meta-Analysis. *Pathogens* 2022; **11**: 659.
- 499 55. Schwarz S, Johnson AP. Transferable resistance to colistin: a new but old threat: Table 1. J
- 500 Antimicrob Chemother 2016; **71**: 2066–70.
- 50. Li Z, Cao Y, Yi L, et al. Emergent Polymyxin Resistance: End of an Era? Open Forum Infect Dis
- 502 2019; **6**: ofz368.
- 503 57. Sreejith S, Manjusha P, Prathuish P, et al. Predicting human risk with multidrug resistant
- 504 Enterobacter hormaechei MS2 with MCR 9 gene isolated from the feces of healthy broiler through
- whole genome sequence based analysis. 2023. Available at: https://www.researchsquare.com.
- 58. Carattoli A, Villa L, Feudi C, et al. Novel plasmid-mediated colistin resistance mcr-4 gene in
- 507 Salmonella and Escherichia coli, Italy 2013, Spain and Belgium, 2015 to 2016. Eurosurveillance
- 508 2017; **22**.
- 509 59. Zurfluh K, Treier A, Schmitt K, et al. Mobile fosfomycin resistance genes in
- 510 Enterobacteriaceae—An increasing threat. *MicrobiologyOpen* 2020; **9**.
- 511 60. Singh S, Pathak A, Kumar A, et al. Emergence of Chromosome-Borne Colistin Resistance Gene
- 512 mcr-1 in Clinical Isolates of Klebsiella pneumoniae from India. Antimicrob Agents Chemother 2018;
- **62**: e01885-17.
- 514 61. Rahman M, Ahmad S. 549. First Report for Emergence of Chromosomal Borne Colistin
- 515 Resistance Gene mcr-1 in a Clinical Acinetobacter Baumannii Isolates from India. Open Forum Infect
- 516 *Dis* 2019; **6**: S261–2.
- 517 62. Pathak A, Singh S, Kumar A, et al. Emergence of chromosome borne colistin resistance gene,
- mcr-1 in clinical isolates of Pseudomonas aeruginosa. *Int J Infect Dis* 2020; **101**: 22.
- 519 63. Seethalakshmi PS, Prabhakaran A, Kiran GS, et al. First Report on the Circulation of mcr-9
- 520 Bearing Enterobacteriaceae Isolated in a Rural Environmental Water Body of India. SSRN Electron J
- 521 2022.
- 522 64. Premnath MAC, Prabakaran K, Sivasankar S, et al. Occurrence of mcr genes and alterations in
- 523 mgrB gene in intrinsic colistin- resistant Enterobacterales isolated from chicken meat samples. Int J
- 524 Food Microbiol 2023; **404**: 110323.

- 525 65. Reddy BRC, Geetha RV, Singh M, et al. Mcr-1 expression in progression of colistin resistance
- 526 gram negative bacilli of clinical specimens derived from Intensive Care Units, wards and hospital
- 527 setting of Deccan Eco Region of Southern India. J Pharm Negat Results 2022; 13. 295-305.
- 528 66. Seethalakshmi PS, Ru VPN, Prabhakaran A, et al. Genomic investigation unveils high-risk ESBL
- 529 producing Enterobacteriaceae within a rural environmental water body. Curr Res Microb Sci 2024; 6:
- 530 100216.
- 531 67. Kieffer N, Royer G, Decousser J-W, et al. mcr-9, an Inducible Gene Encoding an Acquired
- 532 Phosphoethanolamine Transferase in Escherichia coli, and Its Origin. Antimicrob Agents Chemother
- 533 2019; **63**: e00965-19.
- 534 68. Naha S, Basak P, Sands K, et al. Carriage and within-host diversity of mcr-1.1- harbouring
- 535 Escherichia coli from pregnant mothers: inter- and intra-mother transmission dynamics of mcr-1.1.
- 536 *Emerg Microbes Infect* 2023; **12**: 2278899.
- 537 69. Elizabeth R, Baishya S, Kalita B, et al. Colistin exposure enhances expression of eptB in colistin-
- resistant Escherichia coli co-harboring mcr-1. *Sci Rep* 2022; **12**: 1348.
- 70. Bir R, Gautam H, Arif N, et al. Analysis of colistin resistance in carbapenem-resistant
- *Enterobacterales* and XDR *Klebsiella pneumoniae*. *Ther Adv Infect Dis* 2022; **9**: 204993612210806.
- 541 71. Elizabeth R, Wangkheimayum J, Singha KM, Chanda DD, Bhattacharjee A. Subinhibitory
- 542 concentration stress of colistin enhanced PhoPQ expression in Escherichia coli harboring mcr \( \square\) 1. J
- 543 *Basic Microbiol* 2021; **61**: 1029–34.
- 544 72. Roy S, Das P, Das S, et al. Detection of the emergence of mcr-1 -mediated colistin-resistant
- 545 Escherichia coli and Klebsiella pneumoniae through a hospital-based surveillance in an oncology
- center in eastern India. *Infect Control Hosp Epidemiol* 2020; **41**: 378–80.
- 547 73. Subramaniam N, Muthukrishnan A. Oral mucositis and microbial colonization in oral cancer
- 548 patients undergoing radiotherapy and chemotherapy: A prospective analysis in a tertiary care dental
- hospital. J Investig Clin Dent 2019; 10.
- 550 74. Bernasconi OJ, Kuenzli E, Pires J, et al. Travelers Can Import Colistin-Resistant
- 551 Enterobacteriaceae, Including Those Possessing the Plasmid-Mediated mcr-1 Gene. Antimicrob
- 552 *Agents Chemother* 2016; **60**: 5080–4.

**Table 1.** Statistics to test the publication bias and heterogeneity.

Study Name	Egger's Regression Analysis			Het	Model		
(Incidence of Pol <sup>R</sup> bacteria)	Intercept 95% Confidence Interval		P Value Q value (2 tailed)		P- Heterogeneity	I <sup>2</sup> (%)	Used
India	0.37	-2.73 to 3.46	0.81	1515.89	0.00	97.36	Random
Delhi	-6.25	-21.90 to 9.4	0.33	167.66	0.00	97.02	Random
Odisha	2.05	-5.52 to 9.62	0.49	83.95	0.00	94.04	Random
Tamil Nadu	2.62	-6.92 to 12.17	0.53	121.59	0.00	94.24	Random
Uttar Pradesh	0.72	-13.49 to 14.93	0.9	102.7	0.00	94.16	Random
India (Clinical)	-0.15	-3.2 to 2.9	0.92	1164.99	0.00	96.99	Random
India (Environmental)	-4.66	-28.12 to 18.8	0.57	999.46	0.00	97.1	Random
mcr gene in Pol <sup>R</sup>	-1.3	-2.69 to 0.08	0.06	129.71	0.00	69.93	Random

**Table 2**. Detailed information on the *mcr* gene reported from India.


mcr gene	Plasmid/	Bacteria	Source	References
	Chromosomal			
mcr-9	Chromosomal	Enterobacter hormaechei	Clinical isolates	#Seethalakshmi et al., 2024 <sup>66</sup>
mcr-1.1	IncHI2	E. coli (10)	Clinical isolates	Naha et al., 2023 <sup>68</sup>
mcr-4	Not determined	Proteus vulgaris	Poultry meat	Premnath et al., 2023 <sup>64</sup>
mcr-2	Not determined	P. vulgaris, Proteus mirabilis	Poultry meat	Premnath et al., 2023 <sup>64</sup>
mcr-3	Not determined	Morganella morganii (8), P. vulgaris (3), P. mirabilis (2), Providencia rettgeri (4)	Poultry meat	Premnath et al., 2023 <sup>64</sup>
mcr-9.1	IncHI2	E. hormaechei	Broiler faeces	Sreejith et al., 2023 <sup>57</sup>
mcr-5.1	IncX1	E. coli	Hospital sewage water	Talat et al., 2022 <sup>30</sup>
mcr-1	FIA Inc	E. coli	Clinical isolates	Elizabeth et al., 2022 <sup>69</sup>
mcr-1	Not determined	Klebsiella pneumoniae	Clinical isolates	Bir et al., 2022 <sup>70</sup>
mcr-1 (2)	Plasmid	E. $coli$ $(COL^S)*$ , E. $coli$ $(COL^R)$	Clinical isolates	Reddy et al., 2022 <sup>65</sup>
mcr-1 (19)	Chromosomal, Plasmid	Klebsiella pneumoniae (19)	Clinical isolates	Singh et al., 2021 <sup>29</sup>
mcr-1 (2)	Not determined	E. coli (2)	Clinical isolates	Elizabeth et al., 2021 <sup>71</sup>


mcr-1 (4)	Chromosomal	Pseudomonas aeruginosa	Clinical isolates	Singh et al., 2021 <sup>29</sup>
mcr-3.30	Chromosomal	Aeromonas veronii (COL <sup>S</sup> )*	Clinical isolates	Ragupathi et al., 2020 <sup>51</sup>
mcr-1 (2)	Not determined	E. coli	Clinical isolates	Roy et al., 2020 <sup>72</sup>
mcr-1	Not determined	K. pneumoniae	Clinical isolates	Roy et al., 2020 <sup>72</sup>
mcr-1 (2)	IncX4	E. coli	Clinical isolates	Palani et al., 2020 <sup>43</sup>
mcr-1 (2)	Not determined	Enterobacter cloacae	Clinical isolates	Mitra et al., 2020 <sup>50</sup>
mcr-2 (3)	Not determined	Burkholderia cepacia	Clinical isolates	Mitra et al., 2020 <sup>50</sup>
mcr-2	Not determined	Pseudomonas aeruginosa	Clinical isolates	Mitra et al., 2020 <sup>50</sup>
mcr-1	Not determined	Not mentioned	Clinical isolates	Pathak et al., 2020 <sup>62</sup>
<i>mcr-1</i> (5)	Plasmid	E. coli, A. veronii, A.	Sewage water	Gogry et al., 2019 <sup>31</sup>
		dhakensis		
mcr-1	Not determined	E. coli	Clinical isolates	Subramaniam & Muthukrishnan, 2019 <sup>73</sup>
mcr-1 (20)	Chromosomal	Acinetobacter baumannii	Clinical isolates	Rahman & Ahmad., 2019 <sup>61</sup>
mcr-1 (3)	IncX1, IncHI2,	E. coli	Poultry and	Ghafur et al., 2019 <sup>32</sup>
	IncHI2A		mutton meat	
mcr-1 (4)	Chromosomal	K. pneumoniae	Clinical isolates	Singh et al., 2018 <sup>60</sup>
mcr-1	Not determined	Not mentioned	River sediment	Marathe et al., 2017 <sup>49</sup>
mcr-1	Plasmid	E. coli	Clinical isolates	Kumar et al., 2016 <sup>48</sup>
mcr-1	IncHI2	E. coli	Human stool	Bernasconi et al., 2016 <sup>74</sup>
			sample	

Species denoted with \* mark indicate insertional inactivation of the *mcr* gene, which leads to polymyxin susceptibility. The number mentioned in the brackets represents the number of *mcr* reported. # This paper was published in 2023 as an online early version and therefore included in the study.


576

577












# A Delhi




# B Odisha




# C Tamil Nadu





# D Uttar Pradesh











Δ

medRxiv preprint doi: https://doi.org/10.1101/2023.10.04.23296553; this version posted April 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Study name Isiainade available under a CC-BY-NC-ND 4.0 International lieense and 95% ci								/.			
	Event rate	Lower limit	Upper limit	Z-Value	p-Value						Relative weight
Pathak et al., 2023	0.071	0.004	0.577	-1.748	0.081	I	1	<b> </b>		I	2.10
Shanthini et al., 2023	0.018	0.001	0.230	-2.808	0.005			<b>—</b>			2.16
Rout et al., 2023	0.001	0.000	0.010	-5.196	0.000						2.18
Elizabeth et al., 2022	0.417	0.185	0.692	-0.575	0.566			_ L -			3.56
Bir et al., 2022	0.040	0.006	0.235	-3.114	0.002				_		2.81
Naha et al., 2022	0.050	0.003	0.475	-2.029	0.042			<b>-</b>			2.12
Sharma et al, 2022	0.019	0.001	0.244	-2.753	0.006			-	.		2.16
Reddy et al., 2022	0.065	0.016	0.224	-3.658	0.000				9		3.31
Das et al., 2022	0.018	0.001	0.230	-2.808	0.005			-	ř.		2.16
Azam et al., 2021	0.042	0.003	0.425	-2.170	0.030			-			2.13
Nirwan et al., 2021	0.026	0.002	0.310	-2.519	0.012				_		2.15
Singh et al., 2021	0.864	0.652	0.955	2.971	0.003					<b>8</b> -1	3.50
Elizabeth et al., 2021	0.333	0.084	0.732	-0.800	0.423					_	3.08
Kar et al., 2021	0.018	0.001	0.230	-2.808	0.005			<u> </u>	i		2.16
Bandyopadhyay et al., 2021	0.167	0.010	0.806	-1.039	0.299			-			1.99
Pathak et al., 2021	0.100	0.038	0.238	-4.169	0.000			1-6			3.65
Aarthi et al., 2020	0.042	0.003	0.425	-2.170	0.030						2.13
Raghupati et al., 2020	0.100	0.014	0.467	-2.084	0.037						2.75
Roy et al., 2020	0.875	0.266	0.993	1.287	0.198					-	2.04
Sharma et al., 2020	0.050	0.003	0.475	-2.029	0.042			<u> </u>			2.12
Bardhan et al., 2020	0.009	0.001	0.123	-3.341	0.001			•			2.17
Khamari et al., 2020	0.167	0.010	0.806	-1.039	0.299			<u> </u>			1.99
Palani et al., 2020	0.047	0.012	0.168	-4.171	0.000						3.33
Mitra et al., 2020	0.083	0.021	0.279	-3.247	0.001			- <b></b> -	_		3.30
Das et al., 2020	0.016	0.001	0.206	-2.907	0.004			-			2.16
Gogry et al., 2019	0.106	0.045	0.231	-4.499	0.000			-	í.		3.73
Shankar et al., 2019	0.008	0.000	0.110	-3.434	0.001			•			2.17
Mathur et al., 2019	0.014	0.001	0.191	-2.973	0.003						2.16
Sundaramoorthy et al., 2019 B	0.167	0.010	0.806	-1.039	0.299			-			1.99
Subramaniam & Muthukrishnan, 2019	0.833	0.194	0.990	1.039	0.299			- 1 -		-	1.99
Amladi et al., 2019	0.033	0.002	0.366	-2.341	0.019			<b>—</b>			2.14
Rahman & Ahmad., 2019	0.976	0.713	0.999	2.594	0.009				_		2.15
Kumar et al., 2018	0.028	0.002	0.322	-2.479	0.013			<b>—</b>	_		2.15
Ghafur et al., 2018	0.042	0.014	0.123	-5.290	0.000			_			3.55
Singh et al., 2018	0.190	0.073	0.412	-2.604	0.009				_		3.61
Aggarwal et al., 2018	0.063	0.004	0.539	-1.854	0.064		- 1	-	$\longrightarrow$		2.11
Mathur et al., 2018	0.056	0.003	0.505	-1.947	0.052		- 1	<b> -</b>			2.12
Manohar et al., 2017	0.017	0.001	0.217	-2.859	0.004		- 1	-			2.16
Pragasam et al., 2017	0.056	0.003	0.505	-1.947	0.052		- 1	<b>-</b>			2.12
Bernasconi et al., 2016	0.200	0.027	0.691	-1.240	0.215		- 1		<del></del>		2.64
	0.084	0.048	0.143	-7.835	0.000		- 1	•		1	
						-1.00	-0.50	0.00	0.50	1.00	

